FILE:JNJ/JNJ-8K-20060417110844.txt.gz
EVENTS:	Other Events
TEXT:
ITEM: Other Events
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2006 JOHNSON & JOHNSON (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or other Commission (I.R.S. Employer jurisdiction File Number) Identification No.) of incorporation) One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (Address of principal executive offices) (zip code) Registrant's telephone number including area code: (732) 524-0400 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) Item 8.01 Other Events During the fiscal first quarter of 2006 the Company adopted SFAS No. 123(R), Share Based Payment. The Company has applied the modified retrospective transition method to implement SFAS No. 123(R). Previously reported financial statements have been restated to reflect SFAS No. 123 disclosure amounts. The following financial information is included in this Form 8-K and reflects the impact of the adoption of SFAS No. 123(R). Exhibit 99.15 Consolidated Statements of Earnings for 1995 - 2005 including the fiscal first, second, third and fourth quarters of 2005 Operating Profit for 2003 - 2005 including the fiscal first, second, third and fourth quarters of 2005 Consolidated Balance Sheets for 2003 -2005 including the fiscal first, second, and third quarters of 2005 Consolidated Statements of Cash Flows for 2003 - 2005 including the fiscal first, second, and third quarter year-to-date of 2005 Summary of Operations and Statistical Data 1995 - 2005 which appears on page 66 of the 2005 Annual Report, filed as Exhibit 13 to the Company's 2005 Form 10-K SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JOHNSON & JOHNSON Date: April 17, 2006 By: /s/ Stephen J. Cosgrove Stephen J. Cosgrove Chief Accounting Officer

Exhibit 99.15 Consolidated Statements of Earnings - 2005 by Quarter (Dollars in Millions Except Per Share Figures) 2005 2005 2005 2005 First Second Third Fourth Quarter Quarter Quarter Quarter Sales to Customers $12,832 12,762 12,310 12,610 Cost of products sold 3,496 3,522 3,354 3,638 Gross Profit 9,336 9,240 8,956 8,972 Selling, marketing and administrative expenses 4,127 4,278 4,161 4,645 Research expense 1,384 1,525 1,539 2,014 Purchased in-process research and development - 353 - 9 Interest income (84) (109) (123) (171) Interest expense, net of portion capitalized 15 15 22 2 Other (income) expense, net (33) (88) (63) (30) 5,409 5,974 5,536 6,469 Earnings before provision for taxes on income 3,927 3,266 3,420 2,503 Provision for taxes on income 1,088 678 882 408 Net earnings $ 2,839 2,588 2,538 2,095 Basic net earnings per share 0.96 0.87 0.85 0.70 Diluted net earnings per share 0.94 0.86 0.85 0.70 Consolidated Statements of Earnings - 1995 to 2005 (Dollars in Millions Except Per Share Figures) 2005 2004 2003 2002 2001 2000 Sales to Customers $50,514 47,348 41,862 36,298 32,317 29,172 Cost of products sold 14,010 13,474 12,231 10,498 9,622 8,987 Gross Profit 36,504 33,874 29,631 25,800 22,695 20,185 Selling, marketing and administrative expenses 17,211 16,174 14,463 12,520 11,510 10,675 Research expense 6,462 5,344 4,834 4,094 3,704 3,186 Purchased in-process research and development 362 18 918 189 105 66 Interest income (487) (195) (177) (256) ( 456) (429) Interest expense, net of portion capitalized 54 187 207 160 153 204 Other (income) expense, net (214) 15 (385) 294 185 (94) 23,388 21,543 19,860 17,001 15,201 13,608 Earnings before provision for taxes on income 13,116 12,331 9,771 8,799 7,494 6,577 Provision for taxes on income 3,056 4,151 2,923 2,522 2,089 1,813 Net earnings $10,060 8,180 6,848 6,277 5,405 4,764 Basic net earnings per share 3.38 2.76 2.31 2.09 1.78 1.59 Diluted net earnings per share 3.35 2.74 2.29 2.06 1.75 1.55 (Dollars in Millions Except Per Share Figures) 1999 1998 1997 1996 1995 Sales to Customers $27,357 23,811 22,522 21,387 18,537 Cost of products sold 8,559 7,711 7,355 7,187 6,352 Gross Profit 18,798 16,100 15,167 14,200 12,185 Selling, marketing and administrative expenses 10,182 8,595 8,215 7,862 6,951 Research expense 2,821 2,538 2,386 2,115 1,789 Purchased in-process research and development - 298 108 - - Interest income (266) (302) (263) (196) (151) Interest expense, net of portion capitalized 255 186 179 176 184 Other (income) expense, net 119 565 248 122 70 13,111 11,880 10,873 10,079 8,843 Earnings before provision for taxes on income 5,687 4,220 4,294 4,121 3,342 Provision for taxes on income 1,554 1,196 1,224 1,179 926 Net earnings $ 4,133 3,024 3,070 2,942 2,416 Basic net earnings per share 1.38 1.01 1.04 1.00 0.86 Diluted net earnings per share 1.34 1.00 1.01 0.97 0.84 Operating Profit - 2005 by Quarter (Dollars in Millions) 2005 2005 2005 2005 First Second Third Fourth Quarter Quarter(1) Quarter Quarter(2) Consumer $ 438 399 408 347 Pharmaceutical 2,076 1,524 1,734 1,031 Medical Devices and Diagnostics 1,448 1,364 1,319 1,109 Segments Total 3,962 3,287 3,461 2,487 Expenses not allocated to segments (3) (35) (21) (41) 16 Worldwide Total $3,927 3,266 3,420 2,503 (1) Includes $302 million and $51 million of In-Process Research & Development (IPR&D) for the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. (2) Includes $9 million of IPR&D in the Medical Devices and Diagnostics segment. (3) Amounts not allocated to segments include interest (income)/expense, minority interest and general corporate (income)/expense. Operating Profit - 2003 to 2005 (Dollars in Millions) 2005 (1) 2004 (2) 2003 (3) Consumer $ 1,592 1,444 1,319 Pharmaceutical 6,365 7,376 5,650 Medical Devices & Diagnostics 5,240 3,924 3,193 Segments Total 13,197 12,744 10,162 Expenses not allocated to segments (4) (81) (413) (391) Worldwide Total $13,116 12,331 9,771 (1) Includes $302 million and $60 million of In-Process Research & Development (IPR&D) for the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. (2) Includes $18 million of IPR&D in the Medical Devices and Diagnostics segment. (3) Includes $737 million of IPR&D in the Pharmaceutical segment and $181 million of IPR&D and $230 million of an arbitration ruling on stent patents in the Medical Devices and Diagnostics segment. (4) Amounts not allocated to segments include interest (income)/expense, minority interest and general corporate (income)/expense. Consolidated Balance Sheets - 2005 by Quarter (Dollars in Millions) 2005 2005 2005 First Second Third Quarter Quarter Quarter Assets Current assets Cash and cash equivalents $ 8,539 12,156 14,825 Marketable securities 5,111 1,005 354 Accounts receivable trade, less allowances for doubtful accounts 7,336 7,379 7,154 Inventories 3,814 3,963 4,015 Deferred taxes on income 1,871 1,911 1,896 Prepaid expenses and other receivables 2,174 2,387 2,415 Total current assets 28,845 28,801 30,659 Marketable securities, non-current 48 49 44 Property, plant and equipment, net 10,237 10,091 10,227 Intangible assets, net 5,999 6,193 6,067 Goodwill, net 5,819 6,002 6,019 Deferred taxes on income 1,027 1,062 1,384 Other assets 3,222 3,135 2,983 Total assets $55,197 55,333 57,383 Liabilities and Shareholders' Equity Current liabilities Loans and notes payable $ 319 304 278 Accounts payable 4,038 3,949 3,684 Accrued liabilities 3,115 3,153 3,164 Accrued rebates, returns and promotions 2,492 2,312 2,120 Accrued salaries, wages and commissions 891 892 1,144 Accrued taxes on income 2,126 1,030 1,657 Total current liabilities 12,981 11,640 12,047 Long-term debt 2,459 2,329 2,139 Deferred taxes on income 389 418 409 Employee related obligations 2,902 2,936 3,055 Other liabilities 2,061 2,061 2,077 Total liabilities 20,792 19,384 19,727 Shareholders' equity Preferred stock- without par value (authorized and unissued 2,000,000 shares) - - - Common stock- par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,842,000 shares) 3,120 3,120 3,120 Note receivable from employee stock ownership plan - - - Accumulated other comprehensive income (648) (805) (751) Retained earnings 38,051 39,633 41,231 40,523 41,948 43,600 Less: common stock held in treasury, at cost 6,118 5,999 5,944 Total shareholders' equity 34,405 35,949 37,656 Total liabilities and shareholders' equity $55,197 55,333 57,383 Consolidated Balance Sheets - 2003 to 2005 (Dollars in Millions) 2005 2004 2003 Assets Current assets Cash and cash equivalents $16,055 9,203 5,377 Marketable securities 83 3,681 4,146 Accounts receivable trade, less allowances for doubtful accounts 7,010 6,831 6,574 Inventories 3,959 3,744 3,588 Deferred taxes on income 1,931 1,814 1,617 Prepaid expenses and other receivables 2,442 2,124 1,784 Total current assets 31,480 27,397 23,086 Marketable securities, non-current 20 46 84 Property, plant and equipment, net 10,830 10,436 9,846 Intangible assets, net 6,185 5,979 6,149 Goodwill, net 5,990 5,863 5,390 Deferred taxes on income 1,138 1,196 1,196 Other assets 3,221 3,122 3,107 Total assets $58,864 54,039 48,858 Liabilities and Shareholders' Equity Current liabilities Loans and notes payable $ 668 280 1,139 Accounts payable 4,315 5,227 4,966 Accrued liabilities 3,529 3,523 2,639 Accrued rebates, returns and promotions 2,017 2,297 2,308 Accrued salaries, wages and commissions 1,166 1,094 1,452 Accrued taxes on income 940 1,506 944 Total current liabilities 12,635 13,927 13,448 Long-term debt 2,017 2,565 2,955 Deferred taxes on income 211 403 780 Employee related obligations 3,065 2,631 2,262 Other liabilities 2,226 1,978 1,949 Total liabilities 20,154 21,504 21,394 Shareholders' equity Preferred stock- without par value (authorized and unissued 2,000,000 shares) - - - Common stock- par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,842,000 shares) 3,120 3,120 3,120 Note receivable from employee stock ownership plan - (11) (18) Accumulated other comprehensive income (755) (515) (590) Retained earnings 42,310 35,945 31,098 44,675 38,539 33,610 Less: common stock held in treasury, at cost 5,965 6,004 6,146 Total shareholders' equity 38,710 32,535 27,464 Total liabilities and shareholders' equity $58,864 54,039 48,858 Consolidated Statements of Cash Flows - 2005 by Quarter (Dollars in Millions) 2005 2005 2005 First Second Third Quarter Quarter Quarter Cash flows from operations Net earnings $ 2,839 5,427 7,965 Adjustments to reconcile net earnings to cash flows: Depreciation and amortization of property and intangibles 515 1,063 1,586 Stock Based Compensation 135 271 405 Purchased in-process research and development - 353 353 Deferred tax provision 53 (212) (552) Accounts receivable allowances 22 (17) (24) Changes in assets and liabilities, net of effects from acquisitions: Increase in accounts receivable (639) (876) (646) (Increase)/decrease in inventories (140) (380) (433) (Decrease)/increase in accounts payable and accrued liabilities (1,509) (1,651) (1,732) Decrease/(increase) in other current and non-current assets 235 578 860 Increase in other current and non-current liabilities 1,124 93 854 Net cash flows from operating activities 2,635 4,649 8,636 Cash flows from investing activities Additions to property, plant and equipment (397) (874) (1,490) Proceeds from the disposal of assets 77 77 152 Acquisitions, net of cash acquired - (693) (747) Purchases of investments (3,824) (4,999) (5,095) Sales of investments 2,340 7,611 8,324 Other (primarily intangibles) (210) (282) (295) Net cash (used)/provided by investing activities (2,014) 840 849 Cash flows from financing activities Dividends to shareholders (847) (1,829) (2,810) Repurchase of common stock (654) (988) (1,164) Proceeds from short-term debt 173 351 537 Retirement of short-term debt (144) (314) (602) Proceeds from long-term debt 4 4 4 Retirement of long-term debt (17) (20) (196) Proceeds from the exercise of stock options/excess tax benefits 285 455 592 Net cash used by financing activities (1,200) (2,341) (3,639) Effect of exchange rate changes on cash and cash equivalents (85) (195) (224) (Decrease)/Increase in cash and cash equivalents (664) 2,953 5,622 Cash and cash equivalents, beginning of period 9,203 9,203 9,203 Cash and cash equivalents, end of period $ 8,539 12,156 14,825 Consolidated Statements of Cash Flows - 2003 to 2005 (Dollars in Millions) 2005 2004 2003 Cash flows from operations Net earnings $10,060 8,180 6,848 Adjustments to reconcile net earnings to cash flows: Depreciation and amortization of property and intangibles 2,093 2,124 1,869 Stock Based Compensation 540 507 537 Purchased in-process research and development 362 18 918 Deferred tax provision (235) (676) (908) Accounts receivable allowances (31) 3 6 Changes in assets and liabilities, net of effects from acquisitions: Increase in accounts receivable (568) (111) (691) (Increase)/decrease in inventories (396) 11 39 (Decrease)/increase in accounts payable and accrued liabilities (911) 607 2,192 Decrease/(increase) in other current and non-current assets 542 (437) (770) Increase in other current and non-current liabilities 343 863 531 Net cash flows from operating activities 11,799 11,089 10,571 Cash flows from investing activities Additions to property, plant and equipment (2,632) (2,175) (2,262) Proceeds from the disposal of assets 154 237 335 Acquisitions, net of cash acquired (987) (580) (2,812) Purchases of investments (5,660) (11,617) (7,590) Sales of investments 9,187 12,061 8,062 Other (primarily intangibles) (341) (273) (259) Net cash used by investing activities (279) (2,347) (4,526) Cash flows from financing activities Dividends to shareholders (3,793) (3,251) (2,746) Repurchase of common stock (1,717) (1,384) (1,183) Proceeds from short-term debt 1,215 514 3,062 Retirement of short-term debt (732) (1,291) (4,134) Proceeds from long-term debt 6 17 1,023 Retirement of long-term debt (196) (395) (196) Proceeds from the exercise of stock options/excess tax benefits 774 684 335 Net cash used by financing activities (4,443) (5,106) (3,839) Effect of exchange rate changes on cash and cash equivalents (225) 190 277 Increase/(Decrease) in cash and cash equivalents 6,852 3,826 2,483 Cash and cash equivalents, beginning of period 9,203 5,377 2,894 Cash and cash equivalents, end of period $16,055 9,203 5,377 Summary of Operations and Statistical Data 1995-2005 (Dollars in Millions Except Per Share Figures) 2005 2004 2003 2002 2001 2000 Sales to customers-U.S. $28,377 27,770 25,274 22,455 19,825 17,316 Sales to customers- International 22,137 19,578 16,588 13,843 12,492 11,856 Total Sales 50,514 47,348 41,862 36,298 32,317 29,172 Cost of products sold 14,010 13,474 12,231 10,498 9,622 8,987 Selling, marketing and administrative expenses 17,211 16,174 14,463 12,520 11,510 10,675 Research expense 6,462 5,344 4,834 4,094 3,704 3,186 Purchased in-process research and development 362 18 918 189 105 66 Interest income (487) (195) (177) (256) (456) (429) Interest expense, net of portion capitalized 54 187 207 160 153 204 Other (income) expense, net (214) 15 (385) 294 185 (94) 37,398 35,017 32,091 27,499 24,823 22,595 Earnings before provision for taxes on income 13,116 12,331 9,771 8,799 7,494 6,577 Provision for taxes on income 3,056 4,151 2,923 2,522 2,089 1,813 Net earnings 10,060 8,180 6,848 6,277 5,405 4,764 Percent of sales to customers 19.9 17.3 16.4 17.3 16.7 16.3 Diluted net earnings per share of common stock $ 3.35 2.74 2.29 2.06 1.75 1.55 Percent return on average shareholders' equity 28.2 27.3 27.1 26.4 24.0 25.3 Percent increase over previous year: Sales to customers 6.7 13.1 15.3 12.3 10.8 6.6 Diluted net earnings per share 22.3 19.7 11.2 17.7 12.9 15.7 Supplementary expense data: Cost of materials and services (1) $22,328 21,053 18,568 16,540 15,333 14,113 Total employment costs 12,364 11,581 10,542 8,942 8,153 7,376 Depreciation and amortization 2,093 2,124 1,869 1,662 1,605 1,592 Maintenance and repairs (2) 510 462 395 360 372 327 Total tax expense (3) 4,285 5,215 3,890 3,325 2,854 2,517 Supplementary balance sheet data: Property, plant and equipment, net 10,830 10,436 9,846 8,710 7,719 7,409 Additions to property, plant and equipment 2,632 2,175 2,262 2,099 1,731 1,689 Total assets 58,864 54,039 48,858 40,984 38,771 34,435 Total shareholders' equity 38,710 32,535 27,464 23,125 24,516 20,585 Long-term debt 2,017 2,565 2,955 2,002 2,217 3,163 Operating cash flow 11,799 11,089 10,571 8,135 8,781 6,889 Common stock information Dividends paid per share $ 1.275 1.095 0.925 0.795 0.700 0.620 Shareowners' equity per share $ 13.01 10.95 9.25 7.79 8.05 6.82 Market price per share (year-end close) $ 60.10 63.42 50.62 53.11 59.86 52.53 Average shares outstanding (millions)-basic 2,973.9 2,968.4 2,968.1 2,998.3 3,033.8 2,993.5 Average shares outstanding (millions)-diluted 3,012.5 3,003.5 3,008.1 3,054.1 3,099.3 3,099.2 Employees (thousands) 115.6 109.9 110.6 108.3 101.8 100.9 (Dollars in Millions Except Per Share Figures) 1999 1998 1997 1996 1995 Sales to customers-U.S $15,532 12,901 11,814 10,851 9,065 Sales to customers- International 11,825 10,910 10,708 10,536 9,472 Total Sales 27,357 23,811 22,522 21,387 18,537 Cost of products sold 8,559 7,711 7,355 7,187 6,352 Selling, marketing and administrative expenses 10,182 8,595 8,215 7,862 6,951 Research expense 2,821 2,538 2,386 2,115 1,789 Purchased in-process research and development - 298 108 - - Interest income (266) (302) (263) (196) (151) Interest expense, net of portion capitalized 255 186 179 176 184 Other (income) expense, net 119 565 248 122 70 21,670 19,591 18,228 17,266 15,195 Earnings before provision for taxes on income 5,687 4,220 4,294 4,121 3,342 Provision for taxes on income 1,554 1,196 1,224 1,179 926 Net earnings 4,133 3,024 3,070 2,942 2,416 Percent of sales to customers 15.1 12.7 13.6 13.8 13.0 Diluted net earnings per share of common stock $ 1.34 1.00 1.01 0.97 0.84 Percent return on average shareholders' equity 26.0 21.6 24.3 27.1 27.6 Percent increase over previous year: Sales to customers 14.9 5.7 5.3 15.4 36.3 Diluted net earnings per share 34.0 (1.0) 4.1 15.5 21.7 Supplementary expense data: Cost of materials and services (1) $13,922 11,779 11,702 11,341 9,984 Total employment costs 6,727 6,021 5,634 5,469 4,851 Depreciation and amortization 1,510 1,335 1,117 1,047 886 Maintenance and repairs (2) 322 286 270 285 257 Total tax expense (3) 2,221 1,845 1,811 1,747 1,458 Supplementary balance sheet data: Property, plant and equipment, net 7,155 6,767 6,204 6,025 5,544 Additions to property, plant and equipment 1,822 1,610 1,454 1,427 1,307 Total assets 31,163 29,019 23,634 22,254 19,355 Total shareholders' equity 17,094 14,727 13,319 11,964 9,764 Long-term debt 3,429 2,652 2,084 2,347 2,702 Operating cash flow 5,913 5,104 4,209 4,000 3,436 Common stock information Dividends paid per share $ 0.550 0.490 0.425 0.368 0.320 Shareowners' equity per share $ 5.73 4.95 4.52 4.07 3.46 Market price per share (year-end close) $ 46.63 41.94 32.44 25.25 21.38 Average shares outstanding (millions)-basic 2,978.2 2,973.6 2,951.9 2,938.0 2,820.1 Average shares outstanding (millions)-diluted 3,100.4 3,082.7 3,073.0 3,046.2 2,890.0 Employees (thousands) 99.8 96.1 92.6 91.5 84.2 (1) Net of interest and other income. (2) Also included in cost of materials and services category. (3) Includes taxes on income, payroll, property and other business taxes.


